ARS Pharmaceuticals has recently achieved a milestone with the U.S. Food and Drug Administration (FDA) approval of neffy® (epinephrine nasal spray) 2 mg.

Merck Shares Update on Phase 3 Trial KeyVibe-008 Testing Vibostolimab and Pembrolizumab Combo in Extensive-Stage Small Cell Lung Cancer.

Novartis gets FDA fast-track approval for Fabhalta® (iptacopan), marking it as the inaugural complement inhibitor to lower proteinuria in primary IgA nephropathy (IgAN).

Invenra Showcases Exelixis’ News: Phase 1 Clinical Trial Begins for XB010 in Advanced Solid Tumor Patients.

This study is assessing the safety and tolerability of MTX-474, a human IgG1 antibody created to inhibit EphrinB2 signaling.

Takeda Gains European Commission Clearance for ADZYNMA (Recombinant ADAMTS13), the First Recombinant ADAMTS13 Therapy for cTTP.

The FDA has approved Servier's VORANIGO® (vorasidenib) tablets as the first targeted treatment for Grade 2 IDH-mutant glioma.

NeuroBo Pharmaceuticals, Dong-A ST, and ImmunoForge Sign Agreement to Collaborate on Developing a Monthly DA-1726 Formulation to Treat Obesity.

Aug 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The initial participant in the U.S. joins the phase III global multi-center clinical trial for telitacicept targeting myasthenia gravis, marking a significant milestone.

Elevation Oncology Releases Encouraging Early Results from Phase 1 Trial of EO-3021 in Patients with Advanced Non-Resectable or Metastatic Solid Tumors.

This expansion now encompasses Merck’s investigational product MK-6070, a T-cell engager targeting delta-like ligand 3 (DLL3).